Cephalexin therapy for infectious syphilis

Duncan, W. C.

doi:10.1001/archderm.110.1.77

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the frequency of coinfection with N. gonorrhoeae and Treponema pallidum in certain populations, it is particularly important to evaluate antimicrobial agents intended for use in gonorrhea therapy for their activity against T. pallidum. The efficacy of the related penicillins and cephalosporins (2,3,5,6,10) in syphilotherapy suggests that aztreonam might also prove effective for syphilis. This report describes an evaluation of aztreonam as therapy for syphilis in the rabbit model.…”

mentioning

confidence: 99%

Efficacy of aztreonam in treatment of experimental syphilis in rabbits

Lukehart¹,

Baker‐Zander²,

Holmes³

1984

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Efficacy of aztreonam in treatment of experimental syphilis in rabbits

Lukehart¹,

Baker‐Zander²,

Holmes³

1984

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Since 1968, when cephaloridine (firstgeneration cephalosporins [4]) and 1974 when cephalexin [2] were introduced for the treatment of syphilis, the cephalospo rins are considered such an alternative.…”

Section: Stage) -----------------------------------------------------mentioning

confidence: 99%

Ceftriaxone for the Treatment of Primary and Secondary Syphilis

1989

View full text Add to dashboard Cite

In a multicenter, open, randomized, prospective, comparative study, 28 patients with primary (n = 9) or secondary (n = 19) syphilis were treated with either ceftriaxone or penicillin G. 14 patients received ceftriaxone 4 x 1 g i.m. every 2 days. 14 other patients were treated with penicillin G 1 million IU i.m. daily for 15 days (standard therapy of primary and secondary syphilis). To avoid Herxheimer reaction we applied prednisolone 50–100 mg i.m. before specific treatment. Diagnosis was confirmed by clinical symptoms, dark-field microscopy and serological tests (VDRL titer, TPHA test and 19s-IgM-FTA-abs test or SPHA test). Follow-up examinations during therapy were repeated on days 2,4, 6 (dark-field microscopy, physical examination) and day 14 (VDRL titer). To evaluate therapeutic efficacy, serological controls were repeated 1, 2, 3, 6 and 12 months after therapy (VDRL, SPHA). In all patients, a marked decline (minimum 2-dilution decrease) in VDRL titer and resolution of clinical symptoms were noted. An adverse reaction was seen in 1 patient of the clemizol-penicillin G group (allergic penicillin exanthema). There were no adverse reactions to ceftriaxone. Summing up, there was no detectable difference in clinical and serological response to syphilis treatment either with ceftriaxone or penicillin G. Ceftriaxone, thus can be regarded as an equivalent alternative to penicillin G in the treatment of primary and secondary syphilis.

show abstract